Puma Biotechnology, Inc. Stock News

Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Neratinib's combination with trastuzumab deruxtecan shows intriguing signals, especially in pancreatic cancer, but pivotal data won't arrive until 2026. Alisertib's phase 2 trials in breast and lung cancer are ongoing, but lack of recent data keeps its potential speculative for now.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 18,250 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement I...

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q1 2025 Results Conference Call May 8, 2025 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director Investor Relations Alan Auerbach - President & Chief Executive Officer Jeff Ludwig - Chief Commercial Officer Heather Blaber - VP of Marketing Roger Storms - VP of Sales Maximo Nougues - Chief Financial Officer Conference Call Participants Divya...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology release its 1Q'25 earnings results on May 8 after markets closed and followed with a conference call to discuss operating results.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 12,875 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Ince...

ATHENS, Greece and LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, today announced that it has signed an agreement with Puma Biotechnology, Inc. (NASDAQ: PBYI) to commercialize NERLYNX® (neratinib) in select countries in Eastern Europe and Central Asia. NERLYNX is designe...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced Phase I data of trastuzumab deruxtecan plus neratinib in solid tumors with HER2 alterations was presented at AACR 2025.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 1Q-2025 results after market close on May 8, 2025, and follow with a conference call at 1:30 pm PT/4:30 pm ET.